1396640-59-7
- Product Name：Rezafungin
- Molecular Formula：C63H85N8O17
- Purity：99%
- Molecular Weight：1226.41
Product Details:
CasNo： 1396640-59-7
Molecular Formula： C63H85N8O17
Appearance： White to pale yellow solid
Delivery Time： 2 weeks after order
Throughput： 100KG/Month
Purity： 99%
| Product Name: | Rezafungin |
| Synonyms: | Rezafungin;SP-3025;long-lasting,infection,SP3025,CD 101,antifungal,Fungal,inhibit,echinocandin,CD-101,Inhibitor,Rezafungin,SP 3025;Bexagliflozin Impurity 38;Echinocandin B, 1-[(4R,5R)-4-hydroxy-N2-[[4′′-(pentyloxy)[1,1′:4′,1′′-terphenyl]-4-yl]carbonyl]-5-[2-(trimethylammonio)ethoxy]-L-ornithine]-4-[(4S)-4-hydroxy-4-(4-hydroxyphenyl)-L-allothreonine]-;Rezafungin, 10 mM in DMSO |
| CAS: | 1396640-59-7 |
| MF: | C63H85N8O17 |
| MW: | 1226.41 |
| EINECS: | |
| Product Categories: | |
| Mol File: | 1396640-59-7.mol |
 |
|
| Rezafungin Chemical Properties |
| InChIKey | LNFCWEXGZIEGJW-WIQSWMFQNA-O |
| Safety Information |
| Rezafungin Usage And Synthesis |
| Description | Rezafungin is a novel, once-weekly antifungal being developed for the treatment and prevention of serious fungal infections.Rezafungin is a member of the echinocandin class of drugs. Echinocandins are considered the safest antifungal drugs available and are suggested by the Infectious Disease Society of America (IDSA) as first-line treatment for fungal infections. |
| Uses | Rezafungin (CD-101) is a second generation echinocandin with a similar spectrum and mechanism of action. Along with fosmanogepix, ibrexafungerp, olorofim, and opelconazole, rezafungin heralds a new era in the treatment of fungal infections. |
| Side effects | Adverse effects associated with the use of Rezzayo may include, but are not limited to, the following: hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia. |
| Mechanism of action | Rezafungin is a semi-synthetic echinocandin. Rezafungin inhibits the 1,3-B-D-glucan synthase enzyme complex, which is present in fungal cell walls but not in mammalian cells. This results in the inhibition of the formation of 1,3-B-D-glucan, an essential component of the fungal cell wall of many fungi, including Candida species (spp.). Inhibition of 1,3-B-D-glucan synthesis results in concentration-dependent in vitro fungicidal activity against Candida spp., however, the clinical significance of this activity is unknown. |
| References | [1] Syed, Yahiya Y. “Rezafungin: First Approval.” Drugs 83 9 (2023): 833–840. [2] Desnos-Ollivier, Marie and Fanny Lanternier. “New antifungals development: rezafungin in candidiasis treatment.” Lancet Infectious Diseases 22 3 (2023). |
Relevant Products
-
ApixabanCAS：503612-47-3
-
LR3 -IGF-1CAS：946870-92-4
-
Seladelpar lysineCAS：928821-40-3
